With years of experience in IVD (in vitro diagnostic) antibody development, Creative Biolabs now offers the best guarantee in the industry of IVD antibody development and has successfully launched a series of development services for antibodies against different biomarkers of cholangiocarcinoma, which can provide a basis for the diagnosis, prognosis, and treatment of the cancer. Here, we focus on MAPK13 as a potential biomarker for cholangiocarcinoma.

Introduction of MAPK13

Mitogen-activated protein kinase 13 (MAPK13), also known as stress-activated protein kinase 4 (SAPK4) or P38 delta, is an enzyme that belongs to the mitogen-activated protein (MAP) kinase family. It is a serine/threonine kinase which in human is encoded by the MAPK13 gene and functions as an important component of the MAP kinase signal transduction pathway. MAP kinases function as an integration point for multiple biochemical signals and play a role in a wide range of cellular processes including proliferation, differentiation, transcription regulation, and development. MAPK13 is one of the four p38 MAPKs which has an important function on the cascades of cellular responses induced by extracellular stimuli such as proinflammatory cytokines or physical stress, resulting in direct activation of transcription factors like transcription factor ATF2 and ELK1.

Scheme for CLCA1/MAPK13 signaling to mucus production. Fig.1 Scheme for CLCA1/MAPK13 signaling to mucus production. (Alevy, Y. G., 2012)

MAPK13 Marker for Cholangiocarcinoma

Cholangiocarcinoma (CCA) is the second most common type of hepatobiliary cancer worldwide. It forms in the bile ducts, which carry the digestive fluid bile. It is regarded as an aggressive disease in need of urgent investigative attention. However, the diagnosis and treatment of CCA remain notoriously challenging. Compared with hepatocellular carcinoma (HCC), which is responsive to targeted therapy and radiotherapy, CCA has no certain adjuvant therapy. Therefore, distinguishing CCA from HCC has significant importance in predicting clinical outcomes, patient counseling, and selecting treatment methods. MAPK13 has been identified as a novel marker to distinguish CCA from HCC. MAPK13 is shown to be upregulated in CCA when compared with both HCC and normal liver/bile duct tissues. Moreover, the functional characterization of MAPK13 in human CCA cell lines shows that MAPK13 can promote cell migration and invasion, suggesting a vital role in the metastasis of CCA.

IVD Antibody Development Service for MAPK13 Marker

It is certain that MAPK13 can act as a novel marker for the differential diagnosis of CCA from HCC. MAPK13 may also play a functional role in CCA development and can be considered as a new target for molecular-based therapy. Consequently, IVD antibodies against MAPK13 can be developed to help the prognosis and diagnosis of cholangiocarcinoma. Creative Biolabs is now able to provide the most comprehensive IVD antibody development services targeting MAPK13. The antibodies can be customized for the development of different immunoassay formats, including ELISAs, immunohistochemistry, western blot, and so on. We help develop immunoassays from scratch, offering flexible support in feasibility analysis, protocol design, verification, validation, and production.

Based on our extensive experience and advanced platforms, Creative Biolabs has helped many clients achieve their project goals in an efficient and timely manner. We are therefore confident in offering the best services to customers all over the world. Contact us to get more detailed information.

Reference

  1. Alevy, Y. G., (2012). “IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.” The Journal of clinical investigation, 122(12), 4555-68.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.